- Home
- BCSF vs AKBA Comparison
BCSF vs AKBA Comparison
Compare BCSF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- AKBA
- Stock Information
- Founded
- BCSF 2015
- AKBA 2007
- Country
- BCSF United States
- AKBA United States
- Employees
- BCSF N/A
- AKBA N/A
- Industry
- BCSF Finance/Investors Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- AKBA Health Care
- Exchange
- BCSF Nasdaq
- AKBA Nasdaq
- Market Cap
- BCSF 901.0M
- AKBA 729.1M
- IPO Year
- BCSF 2018
- AKBA 2014
- Fundamental
- Price
- BCSF $13.74
- AKBA $2.12
- Analyst Decision
- BCSF Buy
- AKBA Strong Buy
- Analyst Count
- BCSF 2
- AKBA 6
- Target Price
- BCSF $16.50
- AKBA $6.25
- AVG Volume (30 Days)
- BCSF 378.7K
- AKBA 4.5M
- Earning Date
- BCSF 11-10-2025
- AKBA 11-10-2025
- Dividend Yield
- BCSF 12.88%
- AKBA N/A
- EPS Growth
- BCSF N/A
- AKBA N/A
- EPS
- BCSF 1.66
- AKBA N/A
- Revenue
- BCSF $283,687,000.00
- AKBA $203,733,000.00
- Revenue This Year
- BCSF N/A
- AKBA $43.91
- Revenue Next Year
- BCSF N/A
- AKBA $32.09
- P/E Ratio
- BCSF $8.40
- AKBA N/A
- Revenue Growth
- BCSF N/A
- AKBA 16.75
- 52 Week Low
- BCSF $13.20
- AKBA $1.52
- 52 Week High
- BCSF $19.21
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- BCSF 40.01
- AKBA 31.30
- Support Level
- BCSF $13.85
- AKBA $2.07
- Resistance Level
- BCSF $14.18
- AKBA $3.19
- Average True Range (ATR)
- BCSF 0.27
- AKBA 0.16
- MACD
- BCSF 0.01
- AKBA -0.09
- Stochastic Oscillator
- BCSF 25.00
- AKBA 4.46
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.